Cargando…

Risk factors for discontinuing oral immunotherapy in children with persistent cow milk allergy

BACKGROUND: There are no universally accepted criteria for discontinuing milk oral immunotherapy (MOIT) in patients with persistent cow milk allergy (CMA) and little data are available on predictive risk factors for dropping out from oral immunotherapy (OIT), due to allergic reactions or other reaso...

Descripción completa

Detalles Bibliográficos
Autores principales: Benelli, Elisa, Trombetta, Andrea, Badina, Laura, Andrade, Stefanny, Zamagni, Giulia, Prisco, Antonio, Traini, Eugenio, Barbi, Egidio, Berti, Irene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9208286/
https://www.ncbi.nlm.nih.gov/pubmed/35759227
http://dx.doi.org/10.1002/iid3.668
_version_ 1784729710194851840
author Benelli, Elisa
Trombetta, Andrea
Badina, Laura
Andrade, Stefanny
Zamagni, Giulia
Prisco, Antonio
Traini, Eugenio
Barbi, Egidio
Berti, Irene
author_facet Benelli, Elisa
Trombetta, Andrea
Badina, Laura
Andrade, Stefanny
Zamagni, Giulia
Prisco, Antonio
Traini, Eugenio
Barbi, Egidio
Berti, Irene
author_sort Benelli, Elisa
collection PubMed
description BACKGROUND: There are no universally accepted criteria for discontinuing milk oral immunotherapy (MOIT) in patients with persistent cow milk allergy (CMA) and little data are available on predictive risk factors for dropping out from oral immunotherapy (OIT), due to allergic reactions or other reasons. METHODS: We retrospectively reviewed clinical records of patients with persistent severe CMA undergoing MOIT in a tertiary care center hospital to investigate risk factors associated with discontinuation of OIT. Persistent and severe allergy was defined as the history of systemic reactions and any milk protein‐specific IgE level >85 kU/ml. All patients were first admitted for an in‐hospital rush phase eventually followed by an at‐home dose increase. We evaluated the effect of various factors on two primary outcomes: the highest dose of milk ingested during the in‐hospital rush phase and during the home OIT phase. RESULTS: We identified 391 patients, of whom 131 met the inclusion criteria for the retrospective study, 54 females and 77 males. Data of the home OIT phase were available for 104 patients (27%). Regarding the home OIT outcome, an association for having a cow milk avoiding diet was found with reaching a dose below 10 ml during the in‐hospital rush phase (relative risks [RR]: 2.33, confidence interval [CI]: 0.85; 6.42), an age above than 10 years from the time of admission (RR: 3.29, CI: 0.85; 12.73), and a higher total number of reactions occurred during the hospitalization (RR: 1.54, CI: 1.02; 2.32), whereas the presence of respiratory reactions with wheezing (RR: 1.93, CI: 0.49; 7.61) and an IM adrenaline use was related to a higher risk of having an OIT still in progress (RR: 5.47, CI: 0.33; 7.73). CONCLUSIONS: In this cohort of children with persistent CMA undergoing OIT who presented with respiratory reactions with wheezing, the development of anaphylaxis with the need for IM adrenaline, and age above 10 years were predictors of poor long‐term outcome.
format Online
Article
Text
id pubmed-9208286
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-92082862022-06-27 Risk factors for discontinuing oral immunotherapy in children with persistent cow milk allergy Benelli, Elisa Trombetta, Andrea Badina, Laura Andrade, Stefanny Zamagni, Giulia Prisco, Antonio Traini, Eugenio Barbi, Egidio Berti, Irene Immun Inflamm Dis Original Articles BACKGROUND: There are no universally accepted criteria for discontinuing milk oral immunotherapy (MOIT) in patients with persistent cow milk allergy (CMA) and little data are available on predictive risk factors for dropping out from oral immunotherapy (OIT), due to allergic reactions or other reasons. METHODS: We retrospectively reviewed clinical records of patients with persistent severe CMA undergoing MOIT in a tertiary care center hospital to investigate risk factors associated with discontinuation of OIT. Persistent and severe allergy was defined as the history of systemic reactions and any milk protein‐specific IgE level >85 kU/ml. All patients were first admitted for an in‐hospital rush phase eventually followed by an at‐home dose increase. We evaluated the effect of various factors on two primary outcomes: the highest dose of milk ingested during the in‐hospital rush phase and during the home OIT phase. RESULTS: We identified 391 patients, of whom 131 met the inclusion criteria for the retrospective study, 54 females and 77 males. Data of the home OIT phase were available for 104 patients (27%). Regarding the home OIT outcome, an association for having a cow milk avoiding diet was found with reaching a dose below 10 ml during the in‐hospital rush phase (relative risks [RR]: 2.33, confidence interval [CI]: 0.85; 6.42), an age above than 10 years from the time of admission (RR: 3.29, CI: 0.85; 12.73), and a higher total number of reactions occurred during the hospitalization (RR: 1.54, CI: 1.02; 2.32), whereas the presence of respiratory reactions with wheezing (RR: 1.93, CI: 0.49; 7.61) and an IM adrenaline use was related to a higher risk of having an OIT still in progress (RR: 5.47, CI: 0.33; 7.73). CONCLUSIONS: In this cohort of children with persistent CMA undergoing OIT who presented with respiratory reactions with wheezing, the development of anaphylaxis with the need for IM adrenaline, and age above 10 years were predictors of poor long‐term outcome. John Wiley and Sons Inc. 2022-06-20 /pmc/articles/PMC9208286/ /pubmed/35759227 http://dx.doi.org/10.1002/iid3.668 Text en © 2022 The Authors. Immunity, Inflammation and Disease published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Benelli, Elisa
Trombetta, Andrea
Badina, Laura
Andrade, Stefanny
Zamagni, Giulia
Prisco, Antonio
Traini, Eugenio
Barbi, Egidio
Berti, Irene
Risk factors for discontinuing oral immunotherapy in children with persistent cow milk allergy
title Risk factors for discontinuing oral immunotherapy in children with persistent cow milk allergy
title_full Risk factors for discontinuing oral immunotherapy in children with persistent cow milk allergy
title_fullStr Risk factors for discontinuing oral immunotherapy in children with persistent cow milk allergy
title_full_unstemmed Risk factors for discontinuing oral immunotherapy in children with persistent cow milk allergy
title_short Risk factors for discontinuing oral immunotherapy in children with persistent cow milk allergy
title_sort risk factors for discontinuing oral immunotherapy in children with persistent cow milk allergy
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9208286/
https://www.ncbi.nlm.nih.gov/pubmed/35759227
http://dx.doi.org/10.1002/iid3.668
work_keys_str_mv AT benellielisa riskfactorsfordiscontinuingoralimmunotherapyinchildrenwithpersistentcowmilkallergy
AT trombettaandrea riskfactorsfordiscontinuingoralimmunotherapyinchildrenwithpersistentcowmilkallergy
AT badinalaura riskfactorsfordiscontinuingoralimmunotherapyinchildrenwithpersistentcowmilkallergy
AT andradestefanny riskfactorsfordiscontinuingoralimmunotherapyinchildrenwithpersistentcowmilkallergy
AT zamagnigiulia riskfactorsfordiscontinuingoralimmunotherapyinchildrenwithpersistentcowmilkallergy
AT priscoantonio riskfactorsfordiscontinuingoralimmunotherapyinchildrenwithpersistentcowmilkallergy
AT trainieugenio riskfactorsfordiscontinuingoralimmunotherapyinchildrenwithpersistentcowmilkallergy
AT barbiegidio riskfactorsfordiscontinuingoralimmunotherapyinchildrenwithpersistentcowmilkallergy
AT bertiirene riskfactorsfordiscontinuingoralimmunotherapyinchildrenwithpersistentcowmilkallergy